Viatris Scoops Another Preferred Formulary Listing For Interchangeable Semglee
Prime Therapeutics Decision For Insulin Glargine Biosimilar Follows Express Scripts
Executive Summary
Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.
You may also be interested in...
Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
First Interchangeable Biosimilar Launched In US
Viatris and Biocon have introduced their interchangeable Semglee insulin glargine biosimilar in the US, along with an unbranded interchangeable version, marking the first ever launch of an interchangeable biosimilar. The non-interchangeable version is expected to be phased out rapidly.
Viatris Plots January Investor Day To Flesh Out Longer-Term Roadmap
Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.